HAVCR2 and cancer: Resistance to anti-PD-1 therapy has been observed in the presence of TIM-3+ lymphocytes and galectin-9-expressing MDSC [17].The co-expression of galectin-9 and TIM-3 has been detected in various types of cancer [14,19]. The correlation of galectin-9 expression with better OS (in HCC and CRC) or PFS (in GC and NSCLC) has been shown [20]. The opposite data are available [16].